Join our daily newsletter At The Bell to receive exclusive market insights
- Medical data and technology company HeraMED (HMD) has successfully raised over $2.3 million to progress its commercialisation strategy
- The company issued nearly 26 million shares to new and existing investors for 9 cents per share, a 9.1 discount on the last traded price of 9.9 cents
- Funds from the placement will be spent on HeraMED’s commercialisation strategy and earmarked to support future opportunities
- On the market today, HeraMED closed at 11 cents per share
HeraMED (HMD) has successfully raised over $2.3 million to progress its commercialisation strategy.
The pregnancy monitoring solutions company issued nearly 26 million shares to new and existing investors for 9 cents per share.
The issue price is a 9.1 discount on the last traded price of 9.9 cents and an 18 per cent discount to the five-day volume-weighted average price of 10.98 cents per share.
Funds from the placement will be spent on HeraMED’s commercialisation strategy and will ensure it has enough funds to capitalise on future opportunities.
“I am delighted by the support from both existing and new investors in this placement,” CEO and Co-Founder David Groberman said.
“The funds will enable HeraMED to progress our well-defined commercialisation strategy and ensure we can capitalise on the growing pipeline of opportunities,” he added.
PAC Partners was lead manager to the placement and will receive 6 per cent of the total amount raised under the placement.
On the market today, HeraMED closed at 11 cents per share.
